Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Epidermal growth factor inhibitors].

C Delbaldo1, S Faivre, E Raymond

  • 1Département de médecine, institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 cedex, Villejuif, France.

La Revue De Medecine Interne
|June 20, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unravelling the role of environmentally realistic concentrations of titanium dioxide nanoparticles in altering gametogenesis and gonadal health of female Pacific oysters (Magallana gigas): a histopathological approach.

Aquatic toxicology (Amsterdam, Netherlands)·2025
Same author

Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review.

ESMO open·2024
Same author

Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.

ESMO open·2024
Same author

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.

Oncoimmunology·2020
Same author

First evaluation of neustonic microplastics in the Macaronesian region, NE Atlantic.

Marine pollution bulletin·2020
Same author

Medical oncologists must get more involved in systemic treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same journal

[Atypical low back pain].

La Revue de medecine interne·2026
Same journal

[Polycythemia associated chronic haemolysis].

La Revue de medecine interne·2026
Same journal

[Persistent headaches in a 55 year-old man].

La Revue de medecine interne·2026
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
See all related articles

Targeting Epidermal Growth Factor Receptor (EGFR) with new drugs shows promising results in cancer treatment. These agents, including Cetuximab, Iressa, and Tarceva, are well-tolerated and may enhance chemotherapy and radiotherapy efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinases play a crucial role in cell proliferation and cancer development.
  • Epidermal Growth Factor Receptor (EGFR) is a key tyrosine kinase receptor implicated in various human carcinomas.
  • Targeted therapies are being developed to inhibit EGFR signaling pathways.

Purpose of the Study:

  • To review the role of tyrosine kinases and EGFR in cancer.
  • To discuss the development and preliminary findings of EGFR-targeting agents.
  • To evaluate the potential of these agents in cancer treatment strategies.

Main Methods:

  • Review of existing literature on EGFR inhibitors.
  • Analysis of Phase I, II, and III clinical trial data.

Related Experiment Videos

  • Pharmacokinetic and pharmacodynamic profiling of targeted agents.

    • Main Results:

    • EGFR inhibitors (Cetuximab, Iressa, Tarceva) demonstrate favorable safety and tolerability.
    • Early studies indicate promising anti-tumor activity for these agents.
    • Combination therapies with chemotherapy or radiotherapy are under investigation.

    Conclusions:

    • EGFR-targeted therapies show potential as effective cancer treatments.
    • Further large-scale trials are needed to confirm efficacy.
    • These agents may be valuable additions to multimodal cancer therapy, including combination with other targeted agents.